{"analyses":[{"estimateComment":"A normal score \\< 0 indicates fewer than expected events for the panitumumab plus BSC arm and therefore a longer time to event.","groupDescription":"The primary hypothesis was that panitumumab plus BSC would improve overall survival compared to BSC alone. A comparison between treatments was performed using the log-rank test stratified by the randomization factors at a 5% significance level.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0096","paramType":"Normal score","paramValue":"-2.59","statisticalComment":"Log-rank test stratified by randomization factors: geographic region (Europe vs Asia vs rest of world) and ECOG performance status (0 or 1 vs 2).","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.7","upperLimit":"11.4","value":"10.0"},{"groupId":"OG001","lowerLimit":"5.8","upperLimit":"9.3","value":"7.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"189"},{"groupId":"OG001","value":"188"}],"units":"Participants"}],"description":"Overall survival was defined as the time from the randomization date to the date of death. Participants who had not died by the analysis data cut-off date were censored at their last contact date and participants with survival data obtained after the planned analysis data cut-off date had survival censored at the cut-off date.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received panitumumab administered intravenously 6 mg/kg every 14 days plus best supportive care (BSC) until disease progression, withdrawal of consent, death, or intolerance of study drug.","id":"OG000","title":"Panitumumab + BSC"},{"description":"Participants received best supportive care until disease progression, withdrawal of consent, or death.","id":"OG001","title":"BSC Alone"}],"paramType":"MEDIAN","populationDescription":"Intent to Treat (ITT) Analysis Set (all randomized participants); participants in the ITT Analysis Set were required to have wild-type KRAS exon 2 (codons 12 and 13, alleles G12A, G12D, G12R, G12C, G12S, G12V, or G13D) per protocol.","reportingStatus":"POSTED","timeFrame":"From randomization to the last on-study or long-term follow-up visit, as of the data cut-off date of 10 June 2014. The median follow-up time was 34.9 weeks (panitumumab plus BSC: 41.0 weeks; BSC alone: 25.5 weeks).","title":"Overall Survival","type":"PRIMARY","unitOfMeasure":"months"}